Treatment of pruritus in horses

Abstract

The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of a condition or disorder selected from a pruritic condition or an allergic condition, of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating pruritus, preferably pruritus associated with a pruritic condition or an allergic condition such as allergic dermatitis, of equine mammals, preferably of horses.

1 . A method of prevention or treatment of a condition or disorder selected from a pruritic condition or an allergic condition of an equine mammal, wherein said method comprises administering an effective amount of a composition to said equine mammal, wherein said comprising comprises:
 (a) a core particle with at least one first attachment site; and   (b) at least one antigen with at least one second attachment site, wherein said at least one antigen is an equine Interleukin-31 antigen (eIL-31 antigen), wherein said eIL-31 antigen comprises a protein with the amino sequence selected from SEQ ID NO:1 or a protein with an amino acid sequence of at least 90% sequence identity with SEQ ID NO:1;   wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond.   
     
     
         2 . The method according to  claim 1 , wherein said condition or disorder is not insect bite hypersensitivity (IBH) of an equine mammal. 
     
     
         3 . The method according to  claim 1 , wherein said composition further comprises:
 (c) a second core particle with at least one first attachment site; and   (d) at least one second antigen with at least one second attachment site, wherein said at least one second antigen is an equine Interleukin-5 antigen (eIL-5 antigen), wherein said eIL-5 antigen comprises a protein with the amino sequence selected from SEQ ID NO:6 or a protein with an amino acid sequence of at least 90% sequence identity with SEQ ID NO:6;   wherein (c) and (d) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond.   
     
     
         4 . The method according to  claim 1 , wherein said eIL-31 antigen comprises a protein with the amino sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5. 
     
     
         5 . The method according to  claim 3 , wherein said eIL-5 antigen comprises a protein with the amino sequence selected from SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10. 
     
     
         6 . The method according to  claim 1 , wherein said core particle is a virus-like particle (VLP). 
     
     
         7 . The method according to  claim 6 , wherein said VLP is derived from a plant virus or is a VLP of an RNA bacteriophage. 
     
     
         8 . The method according to  claim 6 , wherein said VLP is a modified VLP comprising at least one modified VLP polypeptide, wherein said modified VLP polypeptide comprises:
 (a) a VLP polypeptide, and   (b) a T helper cell epitope,
 wherein said VLP polypeptide comprises, 
 (i) an amino acid sequence of a coat protein of a virus, or 
 (ii) a mutated amino acid sequence, wherein the amino acid sequence to be mutated is an amino acid sequence of said coat protein of a virus, and wherein said mutated amino acid sequence and said coat protein of a virus show a sequence identity of at least 90%. 
   
     
     
         9 . The method according to  claim 6 , wherein said VLP is a modified VLP of cucumber mosaic virus (CMV), wherein said modified VLP of CMV comprises, at least one modified CMV polypeptide, wherein said modified CMV polypeptide comprises:
 (a) a CMV polypeptide, and   (b) a T helper cell epitope; and
 wherein said CMV polypeptide comprises: 
 (ii) an amino acid sequence of a coat protein of CMV; or 
 (ii) a mutated amino acid sequence, wherein the amino acid sequence to be mutated is an amino acid sequence of a coat protein of CMV, and wherein said mutated amino acid sequence and said coat protein of CMV show a sequence identity of at least 90%. 
   
     
     
         10 . The method according to  claim 9 , wherein said T helper cell epitope replaces a N-terminal region of said CMV polypeptide, and wherein said N-terminal region of said CMV polypeptide corresponds to amino acids 2-12 of SEQ ID NO:15. 
     
     
         11 . The method according to  claim 9 , wherein said CMV polypeptide comprises, an amino acid sequence of a coat protein of CMV, wherein said amino acid sequence comprises SEQ ID NO:15 or an amino acid sequence having a sequence identity of at least 95% of SEQ ID NO:15; and wherein said amino sequence comprises SEQ ID NO:27, and wherein said T helper cell epitope replaces the N-terminal region of said CMV polypeptide, and wherein said replaced N-terminal region of said CMV polypeptide consists of 11 to 13 consecutive amino acids. 
     
     
         12 . The method according to  claim 9 , wherein said modified CMV polypeptide comprises an amino acid sequence of SEQ ID NO:20 or SEQ ID NO:21. 
     
     
         13 . The method according to  claim 1 , wherein said pruritic condition or said allergic condition is selected from atopic dermatitis, eczema, psoriasis, scleroderma, pruritus, allergic dermatitis, summer eczema (IBH), bacterial folliculitis, dermatophytosis, recurrent urticaria, heaves, inflammatory airway disease, recurrent airway obstruction, airway hyper-responsiveness, chronic obstruction pulmonary disease, and inflammatory processes resulting from autoimmunity. 
     
     
         14 . The method according to  claim 1 , wherein said administration of said composition reduces at least one parameter or symptom associated with said pruritic condition or said allergic condition as compared to said at least one parameter or symptom associated with said pruritic condition or said allergic condition before said administration. 
     
     
         15 . A composition comprising a first composition and a second composition,
 wherein said first composition comprises
 (a) a first core particle with at least one first attachment site; and 
 (b) at least one first antigen with at least one second attachment site, wherein said at least one first antigen is an equine Interleukin-31 antigen (eIL-31 antigen), wherein said eIL-31 antigen comprises, a protein with the amino sequence selected from SEQ ID NO:1 or a protein with an amino acid sequence of at least 90%, sequence identity with SEQ ID NO:1; and wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond; and 
   wherein said second composition comprises
 (c) a second core particle with at least one first attachment site; and 
 (d) at least one second antigen with at least one second attachment site, wherein said at least one second antigen is an equine Interleukin-5 antigen (eIL-5 antigen), wherein said eIL-5 antigen comprises, a protein with the amino sequence selected from SEQ ID NO:6 or a protein with an amino acid sequence of at least 90%, sequence identity with SEQ ID NO:6, and wherein (c) and (d) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond. 
   
     
     
         16 . The method according to  claim 6 , wherein said core particle is a recombinant virus-like particle (VLP). 
     
     
         17 . The method according to  claim 8 , wherein said VLP polypeptide comprises an amino acid sequence of a coat protein of a plant virus. 
     
     
         18 . The method according to  claim 14 , wherein said at least one parameter or symptom associated with said pruritic condition or said allergic condition is the level or severity grade of skin lesions or the level of pruritus. 
     
     
         19 . The method according to  claim 19 , wherein said reduction of said level or severity grade of skin lesions is determined by a symptom lesion scoring test and said reduction of said level of pruritus is determined by a pruritus scoring test. 
     
     
         20 . The method according to  claim 14 , wherein said at least one parameter or symptom associated with said pruritic condition or said allergic condition is the level of pruritus, and wherein said reduction of said level of pruritus is determined by the reduction of scratching at least one location of the body of said equine mammal.